GlassScriptPhysician profile
Kevin D Orr
NPI 1457677197
$2,139.44
in general payments reported to CMS, 2019-2025
19 companies · $307 in 2025
The $307 reported for 2025 was less than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $258 · 2020: $197 · 2021: $212 · 2022: $277 · 2023: $369 · 2024: $519 · 2025: $307.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,195.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,195.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $802.12 | 2019-2025 | General - Pain Management |
| Medtronic, INC. | $326.26 | 2021-2025 | Catalyft Pl Expandable Interbody System, Activos 10 Bone Cement, Intellis Adaptivestim |
| Abbott Laboratories | $168.22 | 2019-2021 | |
| Bolton Medical INC | $167.63 | 2025 | Relay Thoracic Stent-Graft With Plus Delivery System |
| Atricure, INC. | $151.47 | 2024 | |
| Abbvie INC. | $84.72 | 2022-2025 | |
| Medtronic USA, INC. | $65.94 | 2019-2020 | |
| Averitas Pharma INC. | $63.28 | 2023-2024 | Qutenza |
| Spr Therapeutics, INC | $47.43 | 2023-2025 | Sprint Pns System |
| Collegium Pharmaceutical, INC. | $42.65 | 2024-2025 | Belbuca |
| Allergan, INC. | $37.88 | 2022 | |
| Nevro Corp. | $33.86 | 2019 | |
| Abiomed | $31.25 | 2024 | Impella |
| Grt US Holding, INC. | $30.29 | 2022 | |
| Pfizer INC. | $26.12 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pacira Pharmaceuticals Incorporated | $20.50 | 2022 | |
| Avanos Medical | $13.67 | 2023 | Generator |
| Ibsa Pharma INC. | $13.31 | 2023 | Tirosint, Licart |
| Novartis Pharmaceuticals Corporation | $12.84 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Orr listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.